Rivian vs Sanofi

Lawmakers Approve AM Radio Mandate for US Automakers

The US House of Representatives has overwhelmingly passed the AM Radio for Every Vehicle Act, which would require automakers to include AM radio in new vehicles at no extra cost. The bill now heads to the Senate, where it has bipartisan support with key sponsors including Senators Ed Markey and Ted Cruz. Proponents argue AM radio is crucial for emergency alerts, while automakers like Tesla, Rivian, and BMW have been dropping the feature, often citing electromagnetic interference from electric motors. This legislation could impact the automotive and broadcast industries by preserving AM radio's reach. The bill's future hinges on the Senate vote.

• House passed AM Radio for Every Vehicle Act with bipartisan support.
• Bill directs NHTSA to require AM radio in new vehicles as standard equipment.
• Senators Markey and Cruz co-sponsor Senate version with 60 co-sponsors.

8-K Financial Filing Analysis for Rivian (2026-08-27)

Rivian Automotive, Inc. announced that Chief Financial Officer Claire McDonough will resign effective October 30, 2026, to pursue a new opportunity and relocate to the East Coast. The company confirmed that her departure is amicable and involves no disagreements regarding financial reporting, internal controls, operations, or corporate policies. McDonough will remain in her current role through late October to facilitate an orderly transition. To maintain continuity in capital planning and execution, Derek Mulvey, Rivian's Vice President of Finance since 2021, is expected to step in as Interim CFO while the board conducts a comprehensive internal and external search for a permanent successor.

• CFO Claire McDonough submitted her resignation on August 24, 2026, effective October 30, 2026, with no reported accounting or operational disagreements.
• Derek Mulvey, Vice President of Finance since 2021, is designated to serve as Interim CFO upon McDonough's departure.
• Rivian has initiated a formal internal and external search process to identify a permanent Chief Financial Officer.

Investor Guide: TechCrunch Disrupt 2026

TechCrunch’s investor guide to Disrupt 2026 outlines how investors can use the October 13–15 conference at Moscone West to source startups, network, and gather market intelligence. Highlights include access to 200 vetted, pre-Series A startups in the Startup Battlefield 200 (competing for $100,000 in equity-free funding), curated investor programming across multiple stages (Smart Money, Smart Systems, AI), and Investor Pass perks such as the Deal Flow Café, an early founder list, and AI-assisted curated 1:1 meetings. The article notes past speakers and this year’s speaker lineup, the volume of curated meetings, and time-limited ticket discounts of up to $300 (discount period referenced in the article).

• TechCrunch Disrupt 2026 is scheduled for October 13–15, 2026 at Moscone West in San Francisco.
• Startup Battlefield 200 features 200 pre-Series A startups competing for $100,000 in equity-free funding.
• Startup Battlefield alumni have collectively raised over $32 billion and produced more than 250 exits.

6-K Financial Filing Analysis for Sanofi (2026-09-17)

On September 17, 2026, Sanofi submitted a Form 6-K filing with the U.S. Securities and Exchange Commission incorporating a press release dated September 14, 2026. The filing announces a new strategic partnership between Sanofi and Cheplapharm focused on mature medicines. This partnership reflects Sanofi's ongoing portfolio optimization strategy, allowing the company to streamline operations, monetize or efficiently manage established pharmaceutical assets, and reallocate focus and capital toward core growth drivers and innovative pipeline therapies.

• Sanofi entered into a strategic partnership with Cheplapharm focused on its mature medicines portfolio, originally announced via press release on September 14, 2026.
• The Form 6-K regulatory submission was formally executed and signed on September 17, 2026, by Alexandra Roger, Head of Legal Corporate & Finance.

Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Agentic AI Transforming Pharma Marketing for Rare Diseases

This article discusses how agentic AI is poised to revolutionize pharmaceutical marketing, particularly for rare disease treatments. With traditional drug development costing $2.6 billion and taking 12-15 years, AI is compressing discovery timelines and enabling treatments for smaller patient populations, with rare disease approvals now exceeding 50% of FDA approvals. However, this precision medicine creates a marketing challenge: reaching small, specific audiences efficiently. The article argues that while programmatic advertising optimized campaign execution, agentic AI can synthesize vast healthcare, audience, and market data to provide actionable commercial insights, forecast patient need, and continuously adapt strategies. Early tests show marketing planning cycles collapsing by up to 10x. This approach aims to make more treatments commercially viable, improving treatment economics and driving further investment.

• The pharma industry invests $2.6 billion on average to bring a new treatment to market, taking 12 to 15 years with a 10% success rate.
• Rare disease approvals now account for over 50% of FDA drug approvals, up from below 30% a decade ago.
• Sanofi is developing a 'lab-in-a-loop' using AI agents to compress discovery work from years to weeks.